SINT SINTX TECHNOLOGIES INC.

SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY

SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. () (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer and developer of advanced ceramic materials and related technologies, announced that its wholly owned subsidiary Technology Assessment & Transfer, Inc. (TA&T) has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Army Research Laboratory (DEVCOM ARL). This partnership is expected to leverage the strengths of both organizations in the areas of ceramic additive manufacturing (ceramic 3D printing) and ceramic matrix composites (CMCs).

According to its website, the U.S. Army DEVCOM Army Research Laboratory is the U.S. Army’s research laboratory strategically placed under the Army Futures Command. DEVCOM ARL is the Army’s sole foundational research laboratory focused on cutting-edge scientific discovery, technological innovation, and transitioning capabilities for the future Army (See: ().

SINTX’s Millersville, MD facility, Technology Assessment and Transfer, Inc., began work on ceramic 3D printing in the mid 1990’s, printing its first component in 1998. SINTX now provides prototype and Low-Rate Initial Production (LRIP) ceramic 3D printing services, sells ceramic-filled resins that customers use in their own printing processes, and works with multiple customers in the development of printing solutions for new materials.

In parallel to ceramic 3D printing, SINTX’s Maryland site has also been developing ultra-high temperature CMCs, and building extensive capabilities in the densification of fiber-based preforms using both chemical vapor infiltration and polymer infiltration and pyrolysis. SINTX is excited to participate in the dramatic increase in the market need for these materials in hypersonic vehicle applications as one example.

Ann Kutsch, General Manager of the Maryland site, commented: “We have a highly skilled team of engineers and technicians here in Maryland, all of whom are instrumental in pushing this cutting-edge work forward. I look forward to optimizing our offerings in these markets while also working with DEVCOM ARL to build both teams’ knowledge and capabilities in advanced technologies.”

###

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

For more information on SINTX Technologies or its materials platform, visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA), including, but not limited to, statements regarding SINTX’s ability to effectively develop a range of innovative applications of our ceramic additive manufacturing capabilities, SINTX’s ability to commercialize its technologies and broaden the applications that benefit from such technologies, and other statements that are not based on historical fact. Such forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from current expectations. Risks and uncertainties that may cause such differences include, among other things: SINTX’s products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls and qualification standards; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of SINTX’s products once commercialized; risks related to manufacturing products and market acceptance volatility in the price of SINTX’s common stock; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2023, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business and Media Inquiries for SINTX:

SINTX Technologies

801.839.3502



EN
30/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SINTX TECHNOLOGIES INC.

 PRESS RELEASE

SINTX Technologies to Present at the H.C. Wainwright 27th Annual Globa...

SINTX Technologies to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025 SALT LAKE CITY, Utah, Sept. 09, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that it has been invited to present at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The Company’s presentation is scheduled for Tuesday, ...

 PRESS RELEASE

SINTX Technologies Announces Successful Exercise of Warrants for $3.8 ...

SINTX Technologies Announces Successful Exercise of Warrants for $3.8 Million Gross Proceeds SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,099,431 shares of common stock of the Company originally issued in February 2025, having an exercise price of $3.32 per share. The...

 PRESS RELEASE

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitr...

SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance (PTOL-85) for its patent application titled, “Antipathogenic Fibrous Materials.” The patent secures broad protection for SINTX’s proprietary silicon nitride–based a...

 PRESS RELEASE

SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectr...

SINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the publication of a peer-reviewed study demonstrating that silicon nitride exhibits potent antiviral activity against multiple infectious virus strains, includ...

 PRESS RELEASE

SINTX Technologies Issues Business Update Following Strategic Realignm...

SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch